GLENMARK2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member GLENMARK2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member GLENMARK2020-10-012020-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member GLENMARK2020-10-012020-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member GLENMARK2020-10-012020-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member GLENMARK2020-10-012020-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLENMARK 2020-04-01 2021-03-31 2021-02-01 INR Millions Third quarter Single segment Pharmaceutical 2020-10-01 2020-12-31 Unaudited Consolidated 27867630000.00 150900000.00 28018530000.00 7828980000.00 2532350000.00 -1247660000.00 5966430000.00 954070000.00 1151980000.00 7486810000.00 24672960000.00 3345570000.00 134150000.00 3479720000.00 1212430000.00 -214500000.00 997930000.00 0.00 2481790000.00 0.00 0.00 0.00 0.00 2481790000.00 1046960000.00 3528750000.00 0.00 0.00 3527920000.00 830000.00 282170000.00 1 8.80 8.80 0.00 0.00 8.80 8.80 Single segment 2020-04-01 2020-12-31 Unaudited Consolidated 80840290000.00 417230000.00 81257520000.00 23519300000.00 5726960000.00 -1641780000.00 18065030000.00 2697790000.00 3324850000.00 19561250000.00 71253400000.00 10004120000.00 445450000.00 10449570000.00 3902490000.00 -815060000.00 3087430000.00 0.00 7362140000.00 0.00 0.00 0.00 0.00 7362140000.00 1092150000.00 8454290000.00 0.00 0.00 8452560000.00 1730000.00 282170000.00 1 26.09 26.09 0.00 0.00 26.09 26.09 Other Expenses 7486810000.00 Other Expenses 19561250000.00